NCT04570436View on ClinicalTrials.gov

Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

November 10, 2022

Study Completion Date

November 10, 2022

Conditions
Abuse Potential
Interventions
DRUG

gabapentin 600 mg

participants will receive an oral dose of gabapentin 600 mg

DRUG

gabapentin 1200 mg

participants will receive an oral dose of gabapentin 1200 mg

DRUG

gabapentin 1800 mg

participants will receive an oral dose of gabapentin 1800 mg

DRUG

diazepam 20 mg

participants will receive an oral dose of 20 mg dose of diazepam

OTHER

placebo

participants will receive an oral dose of placebo

Trial Locations (1)

84124

Pharmaceutical Research Associates, Inc., Salt Lake City

All Listed Sponsors
lead

Viatris Specialty LLC

INDUSTRY

NCT04570436 - Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience | Biotech Hunter | Biotech Hunter